DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds...
In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned...
Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal...
